SurModics, Inc. (SRDX)
Develops, manufactures and markets innovative surface modification and drug delivery technologies for the healthcare industry.
Recs
Joel Greenblatt Pick
Recs
Current 24.39, Sept 29 09. Limit 22.55
Recs
Strong sales growth, solid balance sheet, high ROIC, reasonable PE, and no debt. Greenblatt pick.
Recs
Well positioned for growth in healthcare sector. Could be bought by major drug company by the end of 2009. Several things to like for the beaten down price
Recs
Expect takeover by JNJ
Recs
expensive.
Recs
Stent worries overdone. Regardless, this company has real opportunities beyond the stent market.
Recs
Recs
Still has 5 potential opthamology deals to be signed in addition to Merck. Diverse portfolio of customes and products. Great patent coverage. No debt. Recent stock buyback. High short interest due to investors who feel Surmodics is a one trick pony with stents.
Recs
Proposed by Good People
Recs
new antibiotic beads, JNJ business recovering, no debt
Recs
Value of the pipeline is being overwhelmed by the debate on the value of coated stents.
Recs
Will win out in the coated stent race.
Recs
Market for their coatings will increase as boomers age and we all get .... larger.
Recs
Versatile, well protected technology makes anyone's medical device better. Major new business coming.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 15 of 15